Tirzepatide

Tirzepatide is an injectable medication sold under the brand name Mounjaro™. In May, 2022, the FDA approved Tirzepatide for the treatment of Type 2 Diabetes.

This medication in Chandler AZ, along with other injectable medications such as Semaglutide have been shown to be very effective for weight loss. It is critical that such medications be combined with a medically supervised, evidence-based weight loss program to support your efforts. Your weight loss program will help you optimize your weight loss as well as promote long term success.

benefits of Tirzepatide in Chandler AZ

1. Blood Sugar Control: Tirzepatide works well to regulate your blood sugar levels by targeting multiple pathways.
2. Weight Management: It is said that Tirzepatide is being 'fast tracked' as a weight loss medication because of its ability to curb your appetite, promote feelings of fullness and aid in shedding excess weight. This is critical for managing Type 2 Diabetes.
3. Cardiovascular Health: Tirzepatide has shown promising effects on cardiovascular health, potentially reducing the risk of heart-related complications.
4. Convenience: Tirzepatide (similar to Semaglutide injections) is administered just once each week. It also has a convenient dosing schedule as prescribed by your physician, reducing the need for frequent injections.

Potential risks associated with Tirzepatide

1. Hypoglycemia: As with any diabetes medication, there is a risk of low blood sugar levels (hypoglycemia).
2. Gastrointestinal Effects: Some individuals may experience mild gastrointestinal side effects such as nausea, vomiting, constipation, or diarrhea.
3. Pancreatitis: Although rare, there have been instances of pancreatitis reported for those prescribed and utilizing Tirzepatide. Should you experience symptoms such as persistent abdominal pain, it is important to seek medical attention.

At NewVivaMD, we specialize in medical weight loss with and without the use of the latest injectable weight loss medications. If you are interested in learning more, please reach out to us here.